1 Hit in 0.036 sec

TCR Transduction Approach to Expand Severe Graft-Versus-Host Disease Inducing CD4 Specific T Cells

J. Matos, M. Appel, R. Korngold, T. Friedman
2012 Biology of Blood and Marrow Transplantation  
observed in 3 patients (25%). There was no response in 2 patients (16%). The overall response rate at 4 weeks was 83%. Infectious complications were common, including bacteremia (41%), adenovirus viremia (50%), and CMV viremia (33%). Relapse of acute GVHD was observed in 42% of complete responders. Fifty percent of patients are currently surviving at a median follow up time of 775 days following first alemtuzumab course. We conclude that alemtuzumab is an effective treatment for steroid
more » ... for steroid refractory GVHD in pediatric patients with a tolerable spectrum of complications. The dose, timing, and length of treatment should be optimized in a prospective study.
doi:10.1016/j.bbmt.2011.12.434 fatcat:ns4uep3x7zhfronuoql76uhhqu